In Reply

Eric A Coomes; Humaid O Al-Shamsi; Brandon M Meyers; Waleed Alhazzani; Ahmad Alhuraiji; Roy F Chemaly; Meshari Almuhanna; Robert A Wolff; Nuhad K Ibrahim; Melvin L K Chua; Sebastien J Hotte; Tarek Elfiki; Giuseppe Curigliano; Cathy Eng; Axel Grothey; Conghua Xie

doi:10.1634/theoncologist.2020-0329

In Reply

Oncologist. 2020 Aug;25(8):e1252-e1253. doi: 10.1634/theoncologist.2020-0329. Epub 2020 May 27.

Authors

Eric A Coomes¹, Humaid O Al-Shamsi^{2

3

4}, Brandon M Meyers⁵, Waleed Alhazzani⁶, Ahmad Alhuraiji⁷, Roy F Chemaly⁸, Meshari Almuhanna⁹, Robert A Wolff¹⁰, Nuhad K Ibrahim¹¹, Melvin L K Chua^{12

13

14}, Sebastien J Hotte⁵, Tarek Elfiki^{15

16}, Giuseppe Curigliano^{17

18}, Cathy Eng¹⁹, Axel Grothey²⁰, Conghua Xie¹⁴

Affiliations

¹ Division of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Canada.
² Medical Oncology Department, Alzahra Hospital Dubai, Dubai, United Arab Emirates.
³ Department of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
⁴ Emirates Oncology Society, Dubai, United Arab Emirates.
⁵ Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Canada.
⁶ Department of Health Research Methods, Evidence, and Impact and Department of Medicine, McMaster University, Hamilton, Canada.
⁷ Department of Hematology, Kuwait Cancer Control Center, Kuwait City, Kuwait.
⁸ Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁹ Min-Sheng General Hospital, Taoyuan District, Taoyuan City, Taiwan.
¹⁰ Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
¹¹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
¹² Divisions of Radiation Oncology and Medical Sciences, National Cancer Center Singapore, Singapore.
¹³ Oncology Academic Program, Duke-NUS Medical School, Singapore.
¹⁴ Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.
¹⁵ Windsor Regional Cancer Center, Windsor, Canada.
¹⁶ Department of Oncology, Schulich School of Medicine, University of Western Ontario, London, Canada.
¹⁷ Department of Oncology and Hemato-Oncology and Division of Early Drug Development for Innovative Therapy, University of Milan, Milan, Italy.
¹⁸ European Institute of Oncology, IRCCS, Milan, Italy.
¹⁹ Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.
²⁰ West Cancer Center, University of Tennessee, Memphis, Tennessee, USA.

Abstract

This letter to the editor remarks on additional considerations for the management of febrile neutropenia during the COVID‐19 pandemic, in response to the letter by Boutayeb et al.

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Coronavirus Infections*
Febrile Neutropenia*
Humans
Pandemics*
Pneumonia, Viral*
SARS-CoV-2

Grants and funding

Roche/International